Education
About Us
Working with TipRanks
Follow Us
Vivesto AB (SE:VIVE)
:VIVE
VIVE Stock Chart & Stats
kr0.13
>-kr0.01(-0.59%)
At close: 4:00 PM EST
kr0.13
>-kr0.01(-0.59%)
Day’s Range― - ―
52-Week Rangekr0.12 - kr0.36
Previous CloseN/A
Volume772.68K
Average Volume (3M)410.92K
Market Cap
kr70.16M
Enterprise Valuekr118.72M
Total Cash (Recent Filing)kr102.23M
Total Debt (Recent Filing)kr6.98M
Price to Earnings (P/E)―
Beta-0.29
Next Earnings
Feb 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding538,043,460
10 Day Avg. Volume214,919
30 Day Avg. Volume410,918
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.66
Price to Sales (P/S)210.89
P/FCF Ratio-2.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vivesto AB News
VIVE FAQ
What was Vivesto AB’s price range in the past 12 months?
Vivesto AB lowest stock price was kr0.12 and its highest was kr0.35 in the past 12 months.
What is Vivesto AB’s market cap?
Vivesto AB’s market cap is kr70.16M.
When is Vivesto AB’s upcoming earnings report date?
Vivesto AB’s upcoming earnings report date is Feb 12, 2026 which is in 58 days.
How were Vivesto AB’s earnings last quarter?
Vivesto AB released its earnings results on Nov 20, 2025. The company reported -kr0.013 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.013.
Is Vivesto AB overvalued?
According to Wall Street analysts Vivesto AB’s price is currently Overvalued.
Does Vivesto AB pay dividends?
Vivesto AB does not currently pay dividends.
What is Vivesto AB’s EPS estimate?
Vivesto AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivesto AB have?
Vivesto AB has 538,043,460 shares outstanding.
What happened to Vivesto AB’s price movement after its last earnings report?
Vivesto AB reported an EPS of -kr0.013 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -31.224%.
Which hedge fund is a major shareholder of Vivesto AB?
Currently, no hedge funds are holding shares in SE:VIVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivesto AB
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
Technical Analysis
AlzeCure Pharma AB
―
Gabather AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enorama Pharma AB
―